Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc., trading under the ticker LGST, is a clinical-stage biopharmaceutical company focused on T-cell immunotherapy for infectious diseases, oncology, and neurological conditions. The company entered public markets through a de-SPAC merger with Longevity Acquisition Corp, a blank-check vehicle targeting the healthcare and life sciences sector. Following completion of the business combination, Tevogen Bio Holdings filed a 10-K annual report with the SEC on April 17, 2023, reflecting its standing as a publicly reporting operating company in the biotechnology space. Analysts and investors tracking post-merger biopharma SPACs can access complete filings, deal timelines, and historical data for LGST and hundreds of comparable transactions by signing up for full access at SpacDesk.